[Pronostic value of the MDM-2 protein expression in the larynx cancer].
In this paper we carried out an immunohistochemical study of Mdm-2 (IF2) expression in a series of 195 patients with laryngeal carcinoma that were diagnosticated, treated and followed at the Department of Otolaryngology at Virgen de la Salud Hospital (Toledo, Spain). In the cases with lymph node metastasis we also studied Mdm-2 expression at this level. We also wanted to investigate the value of Mdm-2 expression as a prognostic factor (tumor recurrence, deads due to cancer and survival) and we have evaluated the relationship between Mdm-2 expression and other clinic and pathologic characteristics.
García Lozano
M C
MC
Servicio ORL. Hospital Gutiérrez Ortega. Valdepeñas, Ciudad Real. cjangela@castillalamancha.es
Orradre Romero
J L
JL
Martínez Alvarez
A
A
Sáez del Castillo
A I
AI
Piris Pinilla
M A
MA
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality; D002881:Chromosomes, Human, Pair 12 / Q000235:genetics; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000235:genetics* / Q000401:mortality; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000235:genetics*; D010641:Phenotype; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D051736:Proto-Oncogene Proteins c-mdm2
D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2